文献速递白血病

CPX-351联合维奈克拉治疗复发或难治性急性髓系白血病的2期试验

A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia.
PubMed 文献 · Am J Hematol · 2025-05-22

这项单机构1b/2期试验评估CPX-351联合维奈克拉(CPX+VEN)在适合强化化疗的复发/难治性AML患者中的耐受性和疗效。推荐2期剂量为CPX-351(柔红霉素44 mg/m2,第1、3、5天)联合维奈克拉300 mg(第2-8天)。33例患者总缓解率46%(95%CI 30-62),复合完全缓解率39%(95%CI 25-56)。

要点

  • 推荐2期剂量为CPX-351(柔红霉素44 mg/m2,第1、3、5天)联合维奈克拉300 mg(第2-8天)。
  • 33例患者总缓解率46%(95%CI 30-62),复合完全缓解率39%(95%CI 25-56)。
  • 首次挽救治疗且TP53野生型患者复合完全缓解率70%(95%CI 40-89),2年总生存率49%(95%CI 23-100)。

核心结论

  • CPX+VEN在复发/难治性AML中具有活性,尤其在首次挽救治疗和不携带TP53突变的患者中。

研究设计与样本

  • 单机构1b/2期试验,纳入年龄≥18岁、适合强化化疗的复发/难治性AML患者,允许既往维奈克拉暴露。
  • 1b期部分采用3+3设计确定推荐2期剂量,扩展队列共治疗33例患者,中位年龄58岁(范围26-72)。

主要发现

  • 33例患者中58%有既往维奈克拉暴露,44%为第二次挽救或更晚,30%有既往干细胞移植,51%有不良细胞遗传学,64%有骨髓增生异常相关突变,21%有TP53突变。
  • 总缓解率为46%(95%CI 30-62),复合完全缓解率为39%(95%CI 25-56)。
  • 首次挽救且TP53野生型患者复合完全缓解率为70%(95%CI 40-89),可检测残留病阴性率为71%(95%CI 36-92),2年总生存率为49%(95%CI 23-100)。
  • 11例(73%)缓解患者接受了干细胞移植,30天死亡率为9%,60天死亡率为21%。
  • 最常见不良事件与骨髓抑制相关。

关键数值与推荐

  • 推荐2期剂量为CPX-351(柔红霉素44 mg/m2,第1、3、5天)联合维奈克拉300 mg(第2-8天)。
  • 起始剂量水平-1观察到骨髓抑制延长,促使选择剂量水平-2作为推荐2期剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outcomes in patients with relapsed/refractory (RR) AML are poor. We sought to investigate if CPX-531 in combination with venetoclax (CPX + VEN) was tolerable and effective in RR AML. This was a single institution phase 1b/2 trial of CPX + VEN. Patients aged ≥ 18 years with RR AML who were fit for intensive chemotherapy were eligible. Prior venetoclax exposure was allowed. The phase 1b portion followed a 3 + 3 design to identify the recommended phase 2 dose (RP2D) for the expansion cohort. At the starting dose level of -1, prolonged myelosuppression was observed, leading to dose level -2 (CPX-351 dosed at daunorubicin 44 mg/m2 on days 1,3, and 5 and venetoclax 300 mg days 2-8) being chosen as the RP2D. Thirty three patients with a median age of 58 years (range, 26-72) were treated. Patients were heavily pretreated, with 58% with prior venetoclax exposure, 44% in the second salvage or later, and 30% with prior stem cell transplant (SCT). Adverse cytogenetics were present in 51% of patients, with myelodysplasia-related mutations in 64%, and TP53mut in 21%. The overall response rate (ORR) was 46% (95% CI, 30-62), with a composite CR rate (CRc) of 39% (95% CI, 25-56). Patients in first salvage with wildtype TP53 had a CRc rate of 70% (95% CI, 40-89), with undetectable MRD in 71% (95% CI, 36-92) and a 2-year OS of 49% (95% CI, 23-100). Eleven (73%) responding patients underwent SCT. The 30-day mortality was 9%, with a 60-day mortality of 21%. The most common adverse events were related to myelosuppression. CPX + VEN has activity in RR AML, particularly when used in first salvage and in patients who do not harbor TP53 mutations. ClinicalTrials.gov Identifier: NCT03629171.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Kadia TM, Jen WY, Bataller A, et al. A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia. Am J Hematol. 2025. PMID: 40401707. doi:10.1002/ajh.27723

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。